Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Tempescul

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
European Journal of Haematology|April 28, 2015
Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustionAdrian Tempescul, Cristina Bagacean, Catherine Riou, et al.
Leukemia & Lymphoma|April 10, 2013
Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recoveryJean-Christophe Ianotto, Françoise Ngo Sack, Marie-Anne Couturier, et al.
Annals of Hematology|July 26, 2008
A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemiaAdrian Tempescul, Johanna Feuerbach, Jean-Christophe Ianotto, et al.
Annals of Hematology|November 16, 2011
Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapyDivi Cornec, Adrian Tempescul, Solène Querellou, et al.
Biochemia Medica|December 17, 2019
A case of IgE myeloma transformed into IgE-producing plasma cell leukaemiaNicolas Galakhoff, Cyril Leven, Jean-Richard Eveillard, et al.
Biochimica Et Biophysica Acta|July 30, 2014
The arachidonic acid-LTB4-BLT2 pathway enhances human B-CLL aggressivenessNathalie Guriec, Catherine Le Jossic-Corcos, Brigitte Simon, et al.
Clinical Epigenetics|December 7, 2017
Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletionCristina Bagacean, Christelle Le Dantec, Christian Berthou, et al.
Leukemia & Lymphoma|March 11, 2017
Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients onlyChristophe Nicol, Chloé Henry, Marie-Anne Couturier, et al.
Clinical Nuclear Medicine|December 27, 2019
Prognostic Value of Baseline Total Metabolic Tumor Volume Measured on FDG PET in Patients With Richter SyndromeClémence Pontoizeau, Antoine Girard, Habiba Mesbah, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|February 8, 2022
Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteriaNaelle Lombion, Philippe Robin, Adrian Tempescul, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
European Journal of Haematology|April 28, 2015
Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustionAdrian Tempescul, Cristina Bagacean, Catherine Riou, et al.
Leukemia & Lymphoma|April 10, 2013
Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recoveryJean-Christophe Ianotto, Françoise Ngo Sack, Marie-Anne Couturier, et al.
Annals of Hematology|July 26, 2008
A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemiaAdrian Tempescul, Johanna Feuerbach, Jean-Christophe Ianotto, et al.
Annals of Hematology|November 16, 2011
Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapyDivi Cornec, Adrian Tempescul, Solène Querellou, et al.
Biochemia Medica|December 17, 2019
A case of IgE myeloma transformed into IgE-producing plasma cell leukaemiaNicolas Galakhoff, Cyril Leven, Jean-Richard Eveillard, et al.
Biochimica Et Biophysica Acta|July 30, 2014
The arachidonic acid-LTB4-BLT2 pathway enhances human B-CLL aggressivenessNathalie Guriec, Catherine Le Jossic-Corcos, Brigitte Simon, et al.
Clinical Epigenetics|December 7, 2017
Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletionCristina Bagacean, Christelle Le Dantec, Christian Berthou, et al.
Leukemia & Lymphoma|March 11, 2017
Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients onlyChristophe Nicol, Chloé Henry, Marie-Anne Couturier, et al.
Clinical Nuclear Medicine|December 27, 2019
Prognostic Value of Baseline Total Metabolic Tumor Volume Measured on FDG PET in Patients With Richter SyndromeClémence Pontoizeau, Antoine Girard, Habiba Mesbah, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|February 8, 2022
Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteriaNaelle Lombion, Philippe Robin, Adrian Tempescul, et al.
Pageof 7